乳腺癌精准医疗

预约门诊
打印

科室与专家门诊

妙佑医疗国际是美国规模最大、经验最丰富的医疗机构之一，在亚利桑那州、佛罗里达州和明尼苏达州都设有院区。我们的工作人员涉及数十种专业，通过齐心协力确保高品质治疗与成功康复。

有相关专长的科室

研究

实验室技术人员的照片

实验室技术人员正在制备用于检测的样本。

妙佑医疗国际的研究人员在推进乳腺癌精准医疗方面拥有悠久的历史。项目包括：

  • 寻找乳腺癌的新疗法
  • 识别可以调节 DNA 修复的酶
  • 识别不能从芳香化酶抑制剂抗癌药物获益的女性亚群
  • 识别 CYP2D6 酶中的遗传变异，这有助于解释为什么某些乳腺癌患者对他莫昔芬无反应
  • 为 CYP2D6 酶活性低的患者开发一种新药来代替他莫昔芬
  • 为芳香化酶抑制剂耐药的女性开发新药
  • 确定为什么有些人对内分泌治疗无反应的机制，然后开发一种新的乳腺癌药物

文献

请参阅美国国家医学图书馆检索服务系统 PubMed 所收录的妙佑医疗国际医生在乳腺癌精准医疗领域的文献目录。

阅读更多有关乳腺癌研究实验室和项目的信息：

  1. 个性化医学中心
  2. 乳腺癌 SPORE

Research Profiles

编辑搜索过滤条件
close

缩小搜索范围

查看所有医生 • 所有位置

来自妙佑医疗国际员工

在 Mayo Clinic 治疗

申请预约
在 Mayo Clinic 治疗
Oct. 19, 2021
打印
  1. Alisertib with or without fulvestrant in treating patients with locally advanced or metastatic, endocrine-resistant breast cancer. https://clinicaltrials.gov/ct2/show/NCT02860000. Accessed Sept. 9, 2017.
  2. BRCA1 and BRCA2: Cancer risk and genetic testing. National Cancer Institute. http://www.cancer.gov/about-cancer/causes-prevention/genetics/brca-fact-sheet. Accessed June 13, 2017.
  3. Luo K, et al. A phosphorylation-deubiquitination cascade regulates the BRCA2-RAD51 axis in homologous recombination. Genes & Development. 2016;30:1.
  4. Van Poznak C, et al. Use of biomarkers to guide decisions on systemic therapy for women with metastatic breast cancer: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Oncology Practice. 2015;11:514.
  5. Goetz MP (expert opinion). Mayo Clinic, Rochester, Minn. Sept. 26, 2017.
  6. Gradishar WJ, et al. Invasive breast cancer version 1.2016. Clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network. 2016;14:324.
  7. Studying genes. National Institute of General Medical Sciences. https://www.nigms.nih.gov/Education/pages/Factsheet_studyinggenes.aspx. Accessed June 13, 2017.
  8. AskMayoExpert. Genetic testing for BRCA1 and BRCA2 mutations. Rochester, Minn.: Mayo Foundation for Medical Education and Research; 2017.
  9. Mayo Clinic to be home of National Precision Medicine Initiative (PMI) Cohort Program Biobank. News release, Mayo Clinic, Rochester, Minnesota. Sept. 26, 2017.
  10. AskMayoExpert. Breast cancer. Rochester, Minn.: Mayo Foundation for Medical Education and Research; 2015.
  11. Goetz MP, et al. Tumor sequencing and patient-derived xenografts in the neoadjuvant treatment of breast cancer. Journal of the National Cancer Institute. 2017;109:djw306. Accessed June 12, 2017.
  12. Couch FJ, et al. Associations between cancer predisposition testing panel genes and breast cancer. JAMA Oncology. 2017;3:1190.
  13. Hamburg MA, et al. The path to personalized medicine. New England Journal of Medicine. 2010;363:301.
  14. Electronic Medical Records and Genomics (eMERGE) Network. National Human Genome Research Institute. https://www.genome.gov/27540473/electronic-medical-records-and-genomics-emerge-network/#al-2. Accessed June 12, 2017.
  15. Pritchard DE, et al. Strategies for integrating personalized medicine into healthcare practice. Personalized Medicine. 2017;14:141.
  16. The Personalized Medicine Coalition. Personalized Medicine at FDA: 2016 Progress Report. http://www.personalizedmedicinecoalition.org/Resources/Personalized_Medicine_at_FDA. Accessed June 13, 2017.
  17. Peshkin BN. Genetic counseling and testing for hereditary breast and ovarian cancer. http://www.uptodate.com/contents/search. Accessed June 13, 2017.
  18. Raby BA. Personalized medicine. https://www.uptodate.com/contents/search. Accessed June 13, 2017.
  19. Liu T, et al. CDK4/6-dependent activation of DUB3 regulates cancer metastasis through SNAIL1. Nature Communication. 2017;8:13923.
  20. Ingle JN, et al. Genetic polymorphisms in the long noncoding RNA MIR2052HG offer a pharmacogenomics basis for the response of breast cancer patients to aromatase inhibitor therapy. Cancer Research. 2016;76:7012.
  21. Ingle JN, et al. Estrogens and their precursors in postmenopausal women with early breast cancer receiving anastrozole. Steroids. 2015;99:32.
  22. Goetz MP, et al. CYP2D6 metabolism and patient outcome in the Austrian Breast and Colorectal Cancer Study Group trial (ABCSG) 8. Clinical Cancer Research. 2013;19:500.
  23. Goetz MP, et al. First-in-human phase I study of the tamoxifen metabolite Z-endoxifen in women with endocrine-refractory metastatic breast cancer. Journal of Clinical Oncology. In press. Accessed Oct. 17, 2017.
  24. D'Assoro AB, et al. The mitotic kinase Aurora-A promotes distant metastases by inducing epithelial-to-mesenchymal transition in Era(+) breast cancer cells. Oncogene. 2014;33:599.

相关

产品与服务

乳腺癌精准医疗